Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)

Trial Profile

A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Equecabtagene autoleucel (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms FUMANBA-2
  • Sponsors Nanjing IASO Biotherapeutics

Most Recent Events

  • 15 Jun 2024 According to a Nanjing IASO Biotherapeutics media release, as of January 25th, 2024, 16 subjects received Eque-cel therapy.
  • 15 Jun 2024 Results presented in the Nanjing IASO Biotherapeutics Media Release.
  • 15 Jun 2024 According to a Nanjing IASO Biotherapeutics media release, results from this trial were presented at the 2024 European Hematology Association (EHA) Annual Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top